BioMotiv, a company focused on turning breakthrough discoveries from research institutions into drugs, will work with Yale University and will be solely responsible for research and development for Anteros.
Bristol-Myers will contribute the IP, data and reagents for Anteros.
Anteros is the first of several companies Biomotiv and Bristol-Myers plan to form.
Read the full news release here.
More articles on pharmacy:
Walgreens pays $7.5M to resolve claims an employee impersonated a pharmacist
SwedishAmerican opens ScriptCenter, a self-serve pharmacy kiosk
Walgreens CEO talks strategy, skips buyout speculation at annual meeting
